RecruitingNot ApplicableNCT07081152

Iron Absorption and Losses in Young South African Women Living Without and With Overweight and Obesity

Long-term Iron Absorption and Losses in Young South African Women Living Without and With Overweight and Obesity


Sponsor

Linda Malan

Enrollment

70 participants

Start Date

Jul 24, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

Young women living with obesity (OB) have a greater risk of developing iron deficiency. Plus, the risk of anemia and/or ID in young women living with overweight (OW) and obesity (OB) is further increased by inadequate dietary intake and/or poor bioavailability of iron, as well as gastrointestinal and menstrual iron losses. It is not certain whether women living with OW/OB can meet their iron requirements from their day-to-day diet. The aim of this study is to compare iron absorption and losses over a long period between women living with and without OW and OB. Secondary outcomes include iron and inflammation status, as well as dietary iron intake.


Eligibility

Sex: FEMALEMin Age: 18 YearsMax Age: 35 Years

Plain Language Summary

Simplified for easier understanding

This study is comparing iron absorption from food and iron losses over time between young South African women of African descent who are overweight or obese versus those with a healthy weight, to understand whether excess body fat impairs the ability to meet daily iron needs. Obesity-related inflammation is known to raise a hormone called hepcidin that blocks iron absorption, but how this plays out over months in real-life eating patterns has not been well studied. Women of African descent aged between 18 and approximately 45, with low-to-moderate iron stores and specific BMI criteria (either 18.5–24.9 for healthy weight or 28 or higher for overweight/obese) are eligible, while those who are pregnant, anemic (hemoglobin below 11 g/dL), donating blood, or on anti-inflammatory medications are excluded. Participation involves drinking a test drink labeled with a stable iron isotope, blood draws at multiple time points over about 18 months, and completing dietary recall interviews. This summary was prepared to help patients understand the study in plain language.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERFerrous sulfate

All participants will receive a single dose of 15 mg of iron as isotopically prepared ferrous sulfate labelled with 57Fe. The iron dose will be given with ascorbic acid to attain a molar ratio of ascorbic acid:iron of 2:1


Locations(1)

Esté Vorster Research Facility

Potchefstroom, North West, South Africa

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07081152


Related Trials